Masaaki Eto

Summary

Affiliation: Kawasaki Medical School
Country: Japan

Publications

  1. ncbi Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients
    Masaaki Eto
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Am J Kidney Dis 40:243-51. 2002
  2. ncbi Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan
    M Eto
    Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
    Clin Genet 61:416-22. 2002
  3. ncbi Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes
    Mieko Saito
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Metabolism 51:964-9. 2002
  4. ncbi Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients
    Mieko Saito
    Diabetes and Endocrine Division, Department of Internal Medicine, Kawasaki Medical School, Matsushima 577, Kurashiki 701 0192, Japan
    Diabetes Care 27:1276-80. 2004
  5. ncbi Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes
    Masafumi Matsuda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama ken 701 0192
    Eur J Pharmacol 453:141-8. 2002
  6. ncbi Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Oncol Rep 11:1053-8. 2004
  7. ncbi IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Int J Oncol 23:763-8. 2003
  8. ncbi Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review
    Junichi Mukai
    Department of Pharmacy, Akita University Hospital, 1 1 1 Hondo Akita, Akita 010 8543, Japan
    Yakugaku Zasshi 127:1747-56. 2007
  9. ncbi [Case of familial hypoalphalipoproteinemia, type 2 diabetes mellitus and markedly advanced atherosclerosis with ABCAlexon 4 minus transcript in macrophages]
    Mieko Saito
    Moleculan Biology Kawasaki Medical School, Kurashiki
    Nippon Naika Gakkai Zasshi 91:2762-4. 2002
  10. ncbi Plasma lipid levels and nutritional intake in childhood- and adolescence-onset young type 1 diabetic patients in Japan
    Mieko Saito
    School of Pharmaceutical Sciences, Ohu University and Department of Medicine, Ohu University Hospital, Tomita-Misumido 31-1, Koriyama 963-8611, Japan
    Diabetes Res Clin Pract 73:29-34. 2006

Collaborators

Detail Information

Publications10

  1. ncbi Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients
    Masaaki Eto
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Am J Kidney Dis 40:243-51. 2002
    ..The aim of the present study is to further investigate the association between apo E genetic polymorphism, plasma lipid levels (particularly remnant lipoproteins), and diabetic nephropathy...
  2. ncbi Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan
    M Eto
    Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
    Clin Genet 61:416-22. 2002
    ..The patients were characterized by a high frequency of obesity and/or glucose intolerance. The TG-rich lipoproteins from type III HLP patients with diabetes mellitus were more atherogenic...
  3. ncbi Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes
    Mieko Saito
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Metabolism 51:964-9. 2002
    ..RLP from apo E2/2 diabetes with type III HLP are more atherogenic than those from apo E2/2 nondiabetes with type III HLP...
  4. ncbi Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients
    Mieko Saito
    Diabetes and Endocrine Division, Department of Internal Medicine, Kawasaki Medical School, Matsushima 577, Kurashiki 701 0192, Japan
    Diabetes Care 27:1276-80. 2004
    ..The aim of this study was to investigate the effect of apolipoprotein (apo)E4 allele on plasma LDL cholesterol response to calorie-restricted diet therapy in type 2 diabetic patients...
  5. ncbi Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes
    Masafumi Matsuda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama ken 701 0192
    Eur J Pharmacol 453:141-8. 2002
    ..Our results strongly suggest the possibility that chronic intervention with an ATP-sensitive K(+) channel opener prevents the progress of deranged beta-cell function even after the development of diabetes mellitus...
  6. ncbi Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Oncol Rep 11:1053-8. 2004
    ..Based on these findings, statins may be suitable for clinical usage in maintenance therapy for myeloma patients...
  7. ncbi IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Int J Oncol 23:763-8. 2003
    ..Indeed, rhIL-6 abolished pravastatin-induced growth inhibition in KMS-21BM cells which did not express IL-6. Statins may be useful in maintenance therapy for myeloma after the screening of IL-6 status...
  8. ncbi Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review
    Junichi Mukai
    Department of Pharmacy, Akita University Hospital, 1 1 1 Hondo Akita, Akita 010 8543, Japan
    Yakugaku Zasshi 127:1747-56. 2007
    ..The improving effect of (III) on serum lipids may be clinically effective for considering the pathologic condition of diabetes, which is often complicated by hyperlipidemia...
  9. ncbi [Case of familial hypoalphalipoproteinemia, type 2 diabetes mellitus and markedly advanced atherosclerosis with ABCAlexon 4 minus transcript in macrophages]
    Mieko Saito
    Moleculan Biology Kawasaki Medical School, Kurashiki
    Nippon Naika Gakkai Zasshi 91:2762-4. 2002
  10. ncbi Plasma lipid levels and nutritional intake in childhood- and adolescence-onset young type 1 diabetic patients in Japan
    Mieko Saito
    School of Pharmaceutical Sciences, Ohu University and Department of Medicine, Ohu University Hospital, Tomita-Misumido 31-1, Koriyama 963-8611, Japan
    Diabetes Res Clin Pract 73:29-34. 2006
    ..5g/day, p<0.01) than the childhood group. It is concluded that young Japanese type 1 diabetic patients with onset of adolescence have lipid abnormalities, which may be mainly caused by westernized dietary habits...